Altimmune (ALT) Retained Earnings (2010 - 2026)
Altimmune (ALT) posted quarterly Retained Earnings of -$5.2 million for Q1 2026, up 99.1% year-over-year from -$2.6 million in Q1 2025, and down 6.01% quarter-over-quarter from -$4.9 million in Q4 2025.
Altimmune (ALT) Retained Earnings (2010 - 2026) Analysis & Trends
Altimmune (ALT) has reported Retained Earnings for 17 consecutive years, with -$5.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 99.1% year-over-year to -$5.2 million; the TTM figure through Mar 2026 stood at -$5.2 million (up 99.1% YoY), while the FY2025 annual figure was -$4.9 million, up 0.9% from the prior year.
- Retained Earnings declined to -$5.2 million in Q1 2026 per ALT's latest filing, from -$4.9 million in the prior quarter.
- Across five years, Retained Earnings topped out at $676.4 million in Q3 2024 and bottomed at -$581.0 million in Q1 2025.
- Historically, Retained Earnings has averaged $94.5 million across 5 years, with a median of -$5.0 million in 2025.
- Annual changes were most pronounced in 2022 — Retained Earnings tumbled 6103.16% — and 2024, when it surged 13211.47%.
- Altimmune's Retained Earnings stood at $568.4 million in 2022, then sank by 182.04% to -$466.3 million in 2023, then jumped by 98.93% to -$5.0 million in 2024, then gained by 0.9% to -$4.9 million in 2025, then declined by 6.01% to -$5.2 million in 2026.
- Business Quant data shows ALT's Retained Earnings at -$5.2 million in Q1 2026, -$4.9 million in Q4 2025, and -$5.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Altimmune | 571.75 Mn | 571.75 Mn | - | 1.18 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.18 Bn |
| Mar 31, 2026 | -5.22 Mn |
| Dec 31, 2025 | -4.93 Mn |
| Sep 30, 2025 | -5.02 Mn |
| Jun 30, 2025 | -5.04 Mn |
| Mar 31, 2025 | -580.97 Mn |
| Dec 31, 2024 | -4.97 Mn |
| Sep 30, 2024 | 676.43 Mn |
| Jun 30, 2024 | 673.08 Mn |
| Mar 31, 2024 | 668.82 Mn |
| Dec 31, 2023 | -466.33 Mn |
| Sep 30, 2023 | 590.21 Mn |
| Jun 30, 2023 | -414.02 Mn |
| Mar 31, 2023 | -5.10 Mn |
| Dec 31, 2022 | 568.40 Mn |
| Sep 30, 2022 | 566.55 Mn |
| Jun 30, 2022 | -332.71 Mn |
| Mar 31, 2022 | -312.60 Mn |
| Dec 31, 2021 | -293.17 Mn |
| Sep 30, 2021 | -5.04 Mn |